GRP78 Antibody

GRP78 is a ubiquitously expressed, 78-kDa glucose- regulated protein, and is commonly referred to as an immunoglobin chain binding protein (BiP). The BiP proteins are categorized as stress response proteins because they play an important role in the proper folding and assembly of nascent protein and in the scavenging of misfolded proteins in the endoplasmic reticulum lumen. Translation of BiP is directed by an internal ribosomal entry site (IRES) in the 5' non-translated region of the BiP mRNA. BiP IRES activity increases when cells are heat stressed (1). GRP78 is also critical for maintenance of cell homeostasis and the prevention of apoptosis (2). Lou et al. have provided findings that suggest GRP78 is essential for embryonic cell growth and pluripotent cell survival (3). In terms of diseases, GRP78 has been shown to be a reliable biomarker of hypoglycemia, to serve a neuroprotective function in neurons exposed to glutamate and oxidative stress (4), and its protein levels are reduced in the brains of Alzheimer's patients (5). Also, the induction of the GRP78 protein that results in severe glucose and oxygen deprivation could possible lead to drug resistance to anti-tumor drugs (6, 7).

78 kDa glucose regulated protein Antibody, 78 kDa glucose-regulated protein Antibody, AL022860 Antibody, AU019543 Antibody, BIP Antibody, D2Wsu141e Antibody, D2Wsu17e Antibody, Endoplasmic reticulum lumenal Ca(2+)-binding protein grp78 Antibody, Endoplasmic reticulum lumenal Antibody, Ca2+ binding protein grp78 Antibody, FLJ26106 Antibody, Glucose Regulated Protein 78kDa Antibody, GRP 78 Antibody, GRP-78 Antibody, GRP78_HUMAN Antibody, Heat shock 70 kDa protein 5 Antibody, Heat Shock 70kDa Protein 5 Antibody, HSCe70 Antibody, HSPA 5 Antibody, HSPA5 Antibody, Immunoglobulin Heavy Chain Binding Protein Antibody, Immunoglobulin heavy chain-binding protein Antibody, mBiP Antibody, MIF2 Antibody, Sez7 Antibody

1. Cho S., et al. (2007) Mol Cell Biol. 27(1): 368-83. 2. Yang Y., et al. (1998) J Biol Chem 273: 25552-25555. 3. Luo S., et al (2006) 26 (15): 5688-97. 4. Yu Z., et al. (1999) Exp Neurol. 15: 302-314. 5. Koomagi R., et al. (1999) Anticancer Res. 19:4333-4336. 6. Laquerre S., et al. (1998) J. Virology 72: 4940-4949. 7. Dong D., et al. (2005) Cancer Res 65(13): 5785-91.